Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
Abstract Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. Methods N...
Guardado en:
Autores principales: | E. Lin, Hans Garmo, Mieke Van Hemelrijck, Jan Adolfsson, Pär Stattin, Björn Zethelius, Danielle Crawley |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99c33006006c4a96a64c57146bddbb8f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Infiltrative endometriosis and adhesions: is there a cause-and-effect relationship?
por: Mekan R. Orazov, et al.
Publicado: (2021) -
Gonadorelins adherence in prostate cancer: A time‐series analysis of England’s national prescriptions during the COVID‐19 pandemic (from Jan 2019 to Oct 2020)
por: Ravina Barrett, et al.
Publicado: (2021) -
TUMORAL AND NON TUMORAL PITUITARY LESIONS AND REPRODUCTIVE SYSTEM
por: I. A. Ilovayskaya
Publicado: (2012) -
Oxidative stress and biochemical markers in prenatally androgenized sheep after neonatal treatment with GnRH agonist
por: Nóbrega JE, et al.
Publicado: (2019) -
Fixed Gonadotropin-Releasing Hormone Antagonist Protocol Versus Flexible Progestin-Primed Ovarian Stimulation Protocol in Patients With Asynchronous Follicular Development During Controlled Ovulation Stimulation: A Retrospective Study
por: Mei Dong, et al.
Publicado: (2021)